Depo-Provera Brain Tumor Lawsuits Lawsuit

The Progesterone Receptor Mechanism

Meningiomas express progesterone receptors (PR) at rates of 60–80%, making them highly sensitive to progestational hormones. Medroxyprogesterone acetate (MPA) — the active ingredient in Depo-Provera — is a potent synthetic progestin that binds to these receptors with high affinity. When MPA binds to progesterone receptors on meningioma cells, it can stimulate proliferation and tumor growth. This mechanism has been documented since at least 1983, when early studies first identified the progesterone-meningioma connection.

The dose-response relationship is critical to the litigation. Depo-Provera delivers 150mg of MPA per injection — a supraphysiological dose that maintains serum MPA levels far above natural progesterone levels for months. With quarterly injections over years, cumulative progestin exposure becomes enormous. The French study (Roland et al., BMJ 2024) found a 5.6x risk increase for long-term users, while the U.S. study found a dose-dependent relationship: 23% increased odds for ≤1 year use, rising to 250% increased odds for >3 years of use.

Upjohn's Troubled FDA History (1967–1992)

The regulatory history of Depo-Provera is central to the litigation. Upjohn Company first sought FDA approval in 1967, but the agency identified cancer concerns — beagle dogs receiving MPA developed breast tumors. The FDA rejected the application. Upjohn reapplied in 1978, and the FDA again rejected it after a seven-year beagle study showed two animals with malignant breast tumors out of 36 tested. A rare FDA Public Board of Inquiry in 1983 also resulted in rejection.

Despite three FDA rejections over 25 years, Depo-Provera was widely used internationally — the WHO included it in its essential medicines list. The FDA finally approved Depo-Provera in October 1992, after Upjohn submitted additional studies. Pfizer acquired Pharmacia & Upjohn in 2002, inheriting both the drug and its regulatory history.

International Regulatory Actions

The international regulatory timeline strengthens the failure-to-warn case. Canada added meningioma to the Depo-Provera label as an adverse reaction in 2015. New Zealand's Medsafe issued an alert in 2024. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the evidence in 2024 and recommended meningioma warnings for all injectable MPA products and oral formulations containing 100mg+ of MPA. The EMA specifically recommended that MPA be contraindicated in patients with existing meningiomas.

The U.S. FDA did not act until December 2025 — and only after rejecting Pfizer's first label supplement attempt in 2024. Plaintiffs argue that Pfizer was aware of the international warnings and could have voluntarily updated the U.S. label at any time through the Changes Being Effected (CBE) regulatory pathway, which allows manufacturers to add safety information without prior FDA approval.

Bone Density Loss and the Black Box Warning

Meningioma is not the only serious Depo-Provera risk. In 2004, the FDA added a black box warning — its most serious safety communication — regarding bone mineral density loss. Long-term Depo-Provera use causes significant calcium loss from bones, increasing fracture risk. The FDA limited recommended use to 2 years unless no alternative contraceptive is adequate. Despite this warning, many women continued receiving injections beyond the 2-year recommendation.

The bone density warning is relevant to the meningioma litigation because it demonstrates a pattern: risks associated with long-term use that Pfizer and the FDA were slow to address. The intersection of bone loss and meningioma risk creates a particularly compelling narrative for women who used Depo-Provera for extended periods.

Clinical Presentation and Diagnosis

Meningiomas grow slowly and symptoms develop gradually, often over years. Common symptoms include persistent headaches that worsen over time, visual changes (blurred vision, double vision, visual field loss), seizures (occurring in over one-third of meningioma patients), hearing loss or tinnitus, weakness or numbness in extremities, cognitive changes and memory problems, and personality or behavioral changes.

Diagnosis requires neuroimaging — typically a contrast-enhanced MRI of the brain. Current clinical guidelines do NOT recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label (December 2025) instructs providers to "monitor patients on Depo-Provera CI for signs and symptoms of meningioma" and to "discontinue Depo-Provera CI if a meningioma is diagnosed." Women experiencing new or worsening headaches, visual changes, or seizures after Depo-Provera use should request brain imaging.